[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344890-105":59,"doc-detail-344890-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-impact-of-the-methylation-status-of-smad4-and-akr1b1-genes-in-a-liquid-biopsy-sample-as-a-prognostic-marker-for-breast-cancer","Clinical impact of the methylation status of SMAD4 and AKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer","","Role of DNA methylation in breast cancer prognosis, especially regarding small mothers against decapentaplegic 4 (SMAD4) and aldo-keto reductase family 1 member B1 (AKR1B1), remains insufficiently characterized. A cohort of 140 participants was stratified into breast cancer (n=80), benign breast lesions (n=30), and healthy controls (n=30). Methylation levels of SMAD4/AKR1B1 were quantified by Methyl II qPCR, with diagnostic performance assessed via ROC analysis. Associations with clinicopathologic features, treatment response, and survival were evaluated using Kaplan–Meier methods. Results show SMAD4/AKR1B1 hypermethylation elevated in cancer versus benign and controls, with worse DFS and OS outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-impact-of-the-methylation-status-of-smad4-and-akr1b1-genes-in-a-liquid-biopsy-sample-as-a-prognostic-marker-for-breast-cancer/344890/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-impact-of-the-methylation-status-of-smad4-and-akr1b1-genes-in-a-liquid-biopsy-sample-as-a-prognostic-marker-for-breast-cancer/344890.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were SMAD4 and AKR1B1 methylation levels measured in the study?","Question",{"text":112,"@type":113},"Methylation levels were quantified using the Methyl II quantitative PCR (qPCR) system on liquid biopsy samples.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did ROC curve analysis show about diagnostic accuracy?",{"text":117,"@type":113},"SMAD4 and AKR1B1 hypermethylation demonstrated superior diagnostic accuracy with AUC values of 0.945 and 0.935, outperforming conventional biomarkers such as CA 15-3 and CEA.",{"name":119,"@type":110,"acceptedAnswer":120},"How did SMAD4 and AKR1B1 hypermethylation relate to patient outcomes?",{"text":121,"@type":113},"SMAD4 and AKR1B1 hypermethylation was associated with worse DFS and OS, and showed significant links with invasive duct carcinoma features and lymph node metastasis, particularly in early stages and high grades.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344890,1790118708,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nClinical impact of the methylation status ofSMAD4 andAKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer  \nMenhaSwellam1,2􀀍, Amal Ramadan1,2, Mohamed Emam Sobeih3 & Noha M. Bakr1,2􀀍  \nThe role of DNA methylation in the prognosis of breast cancer, particularly concerning small mothers against decapentaplegic 4 (SMAD4) and aldo-keto reductase family 1 member B1 (AKR1B1), remains largely unexplored. This study aimed to investigate the clinical role ofSMAD4 andAKR1B1 methylation as noninvasive prognostic biomarkers in breast cancer. The study included 140 individuals. The patients were stratified into two groups based on their diagnostic investigation: women diagnosed with cancer in breast (N = 80) and cases with benign lesions in breast (N = 30). Additionally, a group of subjects considered as healthy served as the control group (N = 30) . Methylation levels of SMAD4 andAKR1B1 were quantified using the Methyl II quantitative PCR system. The methylation specificity and sensitivity were examined through performing a receiver operating characteristic (ROC) curve analysis. The association of the methylation of investigated patterns with breast cancer clinical features and response to treatment was also examined. Survival patterns were assesed using Kaplan-Meier analyses. The outcomes revealed that hypermethylation ofSMAD4 andAKR1B1 was upregulated in cancerous patients relative to the benign group and healthy subjects. Based on the values of the area under the curve (AUC) (0.945 and 0.935, respectively) for SMAD4 andAKR1B1, both markers demonstrated superior diagnostic accuracy, surpassing conventional biomarkers for instance cancer antigen 15 − 3 (CA 15 − 3; AUC= 0.698) as well as carcinoembryonic antigen (CEA; AUC= 0.537) . Remarkably, SMAD4 andAKR1B1 hypermethylation exhibited a significant association with invasive duct carcinoma (IDC), particularly in early stages, high grades, and cases with lymph node metastasis. A significant difference was observed in methylation status concerning both items and treatment response. Additionally, survival outcomes indicated that hypermethylation ofSMAD4 andAKR1B1 was associated with worse DFS and OS. In conclusion, SMAD4 andAKR1B1 methylation may serve as significant epigenetic markers affecting breast cancer prognosis, potentially indicating more aggressive disease and poorer outcomes in these patients.  \nKeywords Breast cancer, DNA methylation, Diagnosis, Prognosis, SMAD4 and AKR1B1  \nAbbreviations  \nBCSMAD4 AKR1B1 ROC OS  \nPFSAUCCA 15 − 3 CEATGF-β  \nEMT  \nBreast cancer  \nSmall mothers against decapentaplegic 4 Aldo-keto reductase family 1 member B1 Receiver operating characteristic Overall survival  \nProgression free survival Area under the curve Cancer antigen 15 − 3  \nCarcinoembryonic antigen Transforming growth factor-β Epithelial mesenchymal transition  \n1Biochemistry Department, Biotechnology Research Institute, National Research Centre, El-Bohouth Street, Dokki, Giza, Egypt. 2High Throughput Molecular and Genetic laboratory, Center of Excellence for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, Egypt. 3Medical Oncology Department, National Cancer Institute, Cairo, Egypt. 􀀍 email: [menhamswellam@gmail.com](menhamswellam@gmail.com); noni_[mb@yahoo.com](mb@yahoo.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nBLBREAST CANCER  \nIDCDCIELISA qPCR LN ROS mTOR MAPKs NF-kB PI3K PIP2  \nPIP3  \nBase like-breast cancer Invasive duct carcinoma Duct carcinoma in situ  \nEnzyme linked immunesorbent assay Quantitative polymerase chain reaction Lymph node  \nReactive oxygen species  \nMammalian target of rapamycin Mitogen-activated protein kinases Nuclear factor kappa BPhosphoinositide-3-kinases Phosphatidylinositol-4,5-bisphosphate Phosphatidylinositol-3,4,5-triphosphate  \nBreast cancer (BC) is categorized asthe fifth major cause of ","cbCaitPsW6pq1pMr","https://ap.wps.com/l/cbCaitPsW6pq1pMr","pdf",2130256,14,"English","# Introduction\n## Epigenetic alterations and DNA methylation in breast cancer\n## SMAD4 and TGF-β signaling in cancer biology\n# Study approach and biomarkers (overview)\n## Quantification by methyl II qPCR\n## Diagnostic performance using ROC analysis\n## Associations with clinical features and survival","[{\"question\":\"How were SMAD4 and AKR1B1 methylation levels measured in the study?\",\"answer\":\"Methylation levels were quantified using the Methyl II quantitative PCR (qPCR) system on liquid biopsy samples.\"},{\"question\":\"What did ROC curve analysis show about diagnostic accuracy?\",\"answer\":\"SMAD4 and AKR1B1 hypermethylation demonstrated superior diagnostic accuracy with AUC values of 0.945 and 0.935, outperforming conventional biomarkers such as CA 15-3 and CEA.\"},{\"question\":\"How did SMAD4 and AKR1B1 hypermethylation relate to patient outcomes?\",\"answer\":\"SMAD4 and AKR1B1 hypermethylation was associated with worse DFS and OS, and showed significant links with invasive duct carcinoma features and lymph node metastasis, particularly in early stages and high grades.\"}]","Clinical impact of the methylation status of SMAD4 and AKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer | PDF",1790055600,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/819093f0c20138f4b5666848d8cc05cf.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60b221614815ecb2d68b28298c4810b7.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9d1e963c25c4d65d1e5e37acd1df82c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a989c03cbf23dbf02f51978006ca39ae.webp",980,1287]